Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cell Cycle

• Publication date

  2008-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.7.18.6701PMID 18769157PMCID PMC2698221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function

  2007cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• Loss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity

  2006cited by this paper
• Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

  2006cited by this paper
• Hsp90 Recognizes a Common Surface on Client Kinases*

  2006cited by this paper
• Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation

  2005cited by this paper
• Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex

  2005cited by this paper
• Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

  2005cited by this paper
• ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

  2003cited by this paper
• Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

  2002cited by this paper
• Geldanamycin Induces ErbB-2 Degradation by Proteolytic Fragmentation*

  2000cited by this paper
• Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

  1997cited by this paper
• c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS

  1996cited by this paper
• p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.

  1996cited by this paper

• SLCO4A1-AS1 promotes colorectal tumourigenesis by regulating Cdk2/c-Myc signalling

  2022cites this paper
• The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer

  2020cites this paper
• Functional principles and regulation of molecular chaperones.

  2019cites this paper
• Emerging Functions of Human IFIT Proteins in Cancer

  2019cites this paper
• Screening Technique for Heat Shock Protein 90 Inhibitors from Natural Products

  2019cites this paper
• 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

  2019cites this paper
• A comparison of cell survival and heat shock protein expression after radiation in normal dermal fibroblasts, microvascular endothelial cells, and different head and neck squamous carcinoma cell lines

  2018cites this paper
• The HSP90 chaperone machinery

  2017cites this paper
• 19 Heat Shock Proteins in Chronic Lymphocytic Leukaemia

  2017cites this paper
• Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.

  2015cites this paper
• Role of Heat Shock Protein 90 in the Cause of Various Diseases: A Potential Therapeutic Target

  2015cites this paper
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Therapeutics , Targets , and Chemical Biology The HSP 90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and-Resistant MET-Driven Tumor Models

  2013cites this paper
• Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy.

  2013cites this paper
• Hsp90 Inhibitors Exhibit Resistance-Free Antiviral Activity against Respiratory Syncytial Virus

  2013cites this paper
• The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

  2013cites this paper
• Non-enzymatic post-translational protein modifications and proteostasis network deregulation in carcinogenesis.

  2013cites this paper
• Quantitative Proteomics Reveals That Hsp90 Inhibition Preferentially Targets Kinases and the DNA Damage Response*□S

  2012cites this paper
• Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program

  2012cites this paper
• Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

  2012cites this paper
• Stratified medicine for cancer therapy.

  2012cites this paper
• Monitoring the Induction of Heat Shock Factor 1/Heat Shock Protein 70 Expression following 17-Allylamino-Demethoxygeldanamycin Treatment by Positron Emission Tomography and Optical Reporter Gene Imaging

  2012cites this paper
• The Role of Heat Shock Proteins in Mammary Neoplasms: A Brief Review

  2012cites this paper
• A Multi-Pronged Modulation of Signaling Pathways in Targeting Breast Cancer Stem Cells.

  2012cites this paper
• Heat Shock Proteins in Chronic Lymphocytic Leukaemia

  2012cites this paper
• Quantitative Proteomics Reveals That Hsp90 Inhibition Preferentially Targets Kinases and the DNA Damage Response*

  2011cites this paper
• Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance

  2011cites this paper
• Hsp 90 Molecular Chaperone Inhibitors : Are We There Yet ?

  2011cites this paper
• Defining the role of HSP90 in the stability of FGFR3 and as a drug target for the treatment of skeletal diseases and cancer

  2011cites this paper
• Differential heat shock protein localization in chronic lymphocytic leukemia

  2010cites this paper
• Hsp90 as a therapeutic target in patients with oesophageal carcinoma

  2010cites this paper
• Geldanamycin selectively targets the nascent form of ERBB3 for degradation

  2010cites this paper
• Cdc37-Hsp90 Complexes Are Responsive to Nucleotide-induced Conformational Changes and Binding of Further Cofactors*

  2010cites this paper
• Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors

  2009cites this paper
• The Complexity of the HIF-1-Dependent Hypoxic Response in Breast Cancer Presents Multiple Avenues for Therapeutic Intervention

  2009cites this paper
• The role of adjuvant agents in treating fungal diseases

  2009cites this paper
• Update on Hsp90 inhibitors in clinical trial.

  2009cites this paper